Clinical Trials Browser

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Phase 2 Completed

43 enrolled 9 charts

Endocrine

Carcinoma, Neuroendocrine

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2 Withdrawn

Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Phase 2 Terminated

9 enrolled

Genitourinary

Diarrhea, Prostatic Neoplasms

NCT00510224 2013-12-11

Sandostatin for Patients With Androgen Independent Prostate Cancer

Phase 2 Terminated

13 enrolled 4 charts

Genitourinary

Prostatic Neoplasms

NCT00004895 2012-06-06

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Phase 2 Completed

GastrointestinalGynecologicOtherSarcoma

Carcinoma, Ovarian Epithelial, Bile Duct Neoplasms, Colonic Neoplasms, Constipation, Intestinal Obstruction, Nausea, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Vomiting, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT00466856 2012-05-18

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Phase 2 Terminated

10 enrolled

EndocrineHead & Neck

Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Neoplasms, Pheochromocytoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT00257426 2012-02-14

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2 Completed

31 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00332696 2011-09-23

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Phase 2 Completed

64 enrolled 17 charts

Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

NCT00005906 2010-04-30

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

Phase 2 Completed

4 enrolled 8 charts

Thoracic

Ascites, Chylous Ascites, Chylothorax, Lymphangiomyoma, Pleural Effusion, Lymphangioleiomyomatosis

NCT00250796 2010-01-07

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

Phase 2 Completed

12 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Clinical Trials

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

LUMEN-1

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

OTIS

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

CEVOREM

Palliative Management of Inoperable Malignant Bowel Obstruction

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

CSMS99

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Sandostatin for Patients With Androgen Independent Prostate Cancer

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma